## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.3% in lower entry zone (4.0-10.0%), top 6% cross-sectional ranking. Short-term MRS_5 (2.5%) confirms momentum alignment. Strong momentum (+4.2% 5-day acceleration). Outperforming sector by 3.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($38.83)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Three Centene health plans fined $1.7 million by state, health officials say**
- Source: The Center Square | 20251231T000904 | Bearish | Relevance: 100%
- Three Centene Corporation health plans have been fined $1.7 million by the California Department of Managed Health Care for failing to meet timely access standards for appointments. The fines were levied against Health Net ($1.2 million), Human Affairs International of California ($300,000), and Health Net Community Solutions, Inc. ($200,000). The department emphasized that timely access to care is a legal right, and the fines aim to ensure health plans comply with these standards, with funds directed toward programs supporting underserved areas and healthcare data collection.

**2. Looking Into Centene Corp's Recent Short Interest**
- Source: Benzinga | 20251230T160254 | Somewhat-Bullish | Relevance: 100%
- Centene Corp's (NYSE: CNC) short interest has decreased by 6.98% since its last report, with 12.59 million shares currently sold short, representing 2.93% of available shares. It would take traders an average of 1.97 days to cover their short positions. Compared to its peers, Centene Corp has less short interest, indicating a potentially more bullish sentiment from investors.

**3. CVS Health Corp.: Dividend Doubts, Strategy Shifts and a Market Struggling to Believe**
- Source: AD HOC NEWS | 20251230T031114 | Neutral | Relevance: 71%
- CVS Health Corp. is facing investor skepticism as its stock slides amidst a pivot to value-based care, concerns over dividend stability, and mixed Wall Street signals. Despite a comprehensive strategy involving retail pharmacies, PBM, insurance, and newly acquired primary and home-care assets, the market remains unconvinced by the long-term transformation given execution risks and reimbursement pressures. While the company's valuation underpins a contrarian bull case due to a defensive model and strong cash flows, the market demands tangible evidence of margin protection and synergy harvesting to shift the bearish sentiment.

**4. Cwm LLC Purchases 59,690 Shares of Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20251228T090534 | Neutral | Relevance: 62%
- Cwm LLC significantly increased its stake in Molina Healthcare (NYSE:MOH) by 364.9%, acquiring 59,690 additional shares to own a total of 76,049 shares valued at approximately $14.55 million. This move comes as Molina Healthcare reported a quarterly EPS miss but an 11% revenue increase, with analysts maintaining a "Hold" rating and an average price target of $196.33 for the stock.

**5. Ethic Inc. Reduces Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251229T101334 | Neutral | Relevance: 61%
- Ethic Inc. reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 17.0% in Q3, selling 6,761 shares and holding 33,008 shares valued at approximately $10.67 million. Despite this reduction, several other institutional investors increased their positions in ELV during recent quarters. Elevance Health reported strong Q3 earnings, beating analyst estimates with an EPS of $6.03 and revenue of $50.09 billion, and it maintains a "Moderate Buy" consensus rating from analysts with an average price target of $396.21.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Volume divergence: price rising (+4.2% MRS) on declining volume (62% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +4.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.64 elevated, pricing in significant growth expectations. Forward P/E 14.3x attractive for 42% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.3B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.64 |
| Forward P/E | 14.3 |
| Current P/E | 20.3 |
| YoY Growth | 42.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.1% to 4.3% (+4.2% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 94th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Below SMA200 (0.96x), long-term trend not supportive. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.34% (CS: 94) | Strong |
| RSI_14 | 63.9 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 0.961x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $41.23
- **Stop Loss:** $38.83 (5.8% risk)
- **Target:** $44.83 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 550
- **Position Value:** $22,676.50
- **Portfolio %:** 22.68%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*